Addus HomeCare (ADUS) Stock Price, News & Analysis

Company Overview

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.

Key Stats

• Today's Range: $98.96 to $100.78
• 50-Day Range: $89.83 to $113.22
• 52-Week Range: $88.96 to $136.72
• Volume: 97,408 shs
• Average Volume: 162,977 shs
• Market Capitalization: $1.83 billion
• P/E Ratio: 23.02
• Dividend Yield: N/A
• Price Target: $139.00
• Consensus Rating: Buy

Addus HomeCare Stock Analysis - MarketRank™

Addus HomeCare scored higher than 93% of companies evaluated by MarketBeat, and ranked 47th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Addus HomeCare has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Addus HomeCare has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 16.78%

Earnings Growth

Earnings for Addus HomeCare are expected to grow by 16.78% in the coming year, from $4.59 to $5.36 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Addus HomeCare is 23.02, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.67.

Price to Earnings Ratio vs. Sector

The P/E ratio of Addus HomeCare is 23.02, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.25.

Price to Earnings Growth Ratio

Addus HomeCare has a PEG Ratio of 1.41. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Addus HomeCare has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.39% of the float of Addus HomeCare has been sold short.

Short Interest Ratio / Days to Cover

Addus HomeCare has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Addus HomeCare has recently increased by 18.06%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Addus HomeCare does not currently pay a dividend.

Dividend Growth

Addus HomeCare does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 5.0 / 5
• Environmental Score: -0.50

Percentage of Shares Shorted

4.39% of the float of Addus HomeCare has been sold short.

Short Interest Ratio / Days to Cover

Addus HomeCare has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Addus HomeCare has recently increased by 18.06%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.33

News Sentiment

Addus HomeCare has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Addus HomeCare this week, compared to 5 articles on an average week.

MarketBeat Follows

Only 1 people have added Addus HomeCare to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Addus HomeCare insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,008.00 in company stock.

Percentage Held by Insiders

Only 4.60% of the stock of Addus HomeCare is held by insiders.

Percentage Held by Institutions

95.35% of the stock of Addus HomeCare is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ADUS Stock Analysis - Frequently Asked Questions

How have ADUS shares performed this year?

Addus HomeCare's stock was trading at $125.35 at the start of the year. Since then, ADUS shares have decreased by 19.8% and is now trading at $100.58.
View the best growth stocks for 2025 here.

How were Addus HomeCare's earnings last quarter?

Addus HomeCare Co. (NASDAQ:ADUS) announced its quarterly earnings results on Monday, February, 24th. The company reported $1.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.35 by $0.09. The firm had revenue of $297.14 million for the quarter, compared to analysts' expectations of $291.04 million. Addus HomeCare had a net margin of 6.50% and a trailing twelve-month return on equity of 9.62%.
Read the conference call transcript.

Who are Addus HomeCare's major shareholders?

Addus HomeCare's top institutional investors include GAMMA Investing LLC (0.72%), Harbor Capital Advisors Inc. (0.35%), Rhumbline Advisers (0.29%) and Bridge City Capital LLC (0.20%). Insiders that own company stock include R Dirk Allison, W Bradley Bickham, Darby Anderson, Brian Poff, Sean Gaffney, Monica Raines, Cliff Donald Blessing, Roberton James Stevenson, Michael D Wattenbarger, David W Tucker and Esteban Lopez.
View institutional ownership trends.

How do I buy shares of Addus HomeCare?

Shares of ADUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Addus HomeCare own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Addus HomeCare investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Eli Lilly and Company (LLY) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 2/24/2025
• Today: 4/26/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Home health care services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:ADUS
• CIK: 1468328
• Web: www.addus.com
• Phone: (469) 535-8200
• Fax: 630-487-2707
• Employees: 33,200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $139.00
• High Stock Price Target: $150.00
• Low Stock Price Target: $118.00
• Potential Upside/Downside: +38.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.22
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $4.24
• Trailing P/E Ratio: 23.02
• Forward P/E Ratio: 21.91
• P/E Growth: 1.41
• Net Income: $62.52 million
• Net Margins: 6.50%
• Pretax Margin: 8.69%
• Return on Equity: 9.62%
• Return on Assets: 7.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.11
• Quick Ratio: 2.11

Sales & Book Value

• Annual Sales: $1.15 billion
• Price / Sales: 1.58
• Cash Flow: $4.65 per share
• Price / Cash Flow: 21.65
• Book Value: $43.58 per share
• Price / Book: 2.31

Miscellaneous

• Outstanding Shares: 18,173,000
• Free Float: 17,299,000
• Market Cap: $1.83 billion
• Optionable: Optionable
• Beta: 0.93